scispace - formally typeset
G

Gerhardt G. Schurig

Researcher at Virginia–Maryland Regional College of Veterinary Medicine

Publications -  87
Citations -  3981

Gerhardt G. Schurig is an academic researcher from Virginia–Maryland Regional College of Veterinary Medicine. The author has contributed to research in topics: Brucella melitensis & Brucella. The author has an hindex of 36, co-authored 87 publications receiving 3810 citations. Previous affiliations of Gerhardt G. Schurig include Virginia Tech & United States Department of the Army.

Papers
More filters
Journal ArticleDOI

Biological properties of RB51; a stable rough strain of Brucella abortus.

TL;DR: A rifampin-resistant mutant of Brucella abortus, designated RB51, was derived by repeated passage of strain 2308 on Trypticase soy supplemented with 1.5% agar and varying concentrations rifampsin or penicillin, indicating a rough type colonial morphology for this strain.
Journal ArticleDOI

Brucellosis vaccines: past, present and future.

TL;DR: Attempts are being made to develop defined rough mutant vaccine strains that would be more effective against B. melitensis and B. suis, with or without adjuvants.
Journal ArticleDOI

Characterization of monoclonal antibodies directed against swine leukocytes

TL;DR: Hybridomas produced from fusions of the SP2/0 mouse myeloma with splenic cells from an outbred Sprague Dawley rat immunized with swine peripheral blood mononuclear (PBM) cells were selected, cloned and characterized by their cell reactivity and effect on mitogenic assays.
Journal ArticleDOI

Identification of an IS711 element interrupting the wboA gene of Brucella abortus vaccine strain RB51 and a PCR assay to distinguish strain RB51 from other Brucella species and strains.

TL;DR: It is demonstrated that thewboA gene encoding a glycosyltransferase, an enzyme essential for the synthesis of O antigen, is disrupted by an IS711 element in B. abortus vaccine strain RB51, a natural stable attenuated rough mutant derived from the virulent strain 2308.
Journal Article

Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.

TL;DR: Results encourage evaluation, in primary host species, of VTRM1 and VTRS1, along with RB51, as alternative vaccines to strain 19, Rev 1, or other smooth phase vaccines.